Comprehensive, Comparative Evaluation of 35 Manual SARS-CoV-2 Serological Assays
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The markets have been flooded with hundreds of SARS-CoV-2 serology tests, and although there are many published reports on their performance, comparative reports are far fewer and tend to be limited to only a few tests. In this report, we comparatively assessed 35 rapid diagnostic tests or microtiter plate enzyme immunoassays (EIAs) using a large set of samples from individuals with a history of mild to moderate COVID-19, commensurate with the target population for serosurveillance, which included serum samples from individuals previously infected, at undetermined time periods, with other seasonal human coronaviruses, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Signi fi cant di ff erences in performance were identi fi ed.”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The National Serology Reference Laboratory, Australia (NRL) was funded by the World Health Organization (WHO) to perform evaluations on 35 SARS-COV-2 serology rapid diagnostic test (RDT) kits [36], with a subsequent evaluation of 25 automated assays [37].”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · cited 1×
“RDTs claiming to detect IgM were used to diagnose recent infections (11, 12).”
MethodAntibody tests for identification of current and past infection with SARS‐CoV‐2
Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 850
Self-citationAntibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Ferrante di Ruffano, L., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 655
Diagnostics for COVID-19: moving from pandemic response to control
Peeling, R. W., Heymann, D. L., Teo, Y.-Y., & Garcia, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02346-1 · Cited by 486 · cited 3×
“The results of this study indicate that the SARS-CoV-2 IgG response is detectable at the same time as or one bleed after the detection of IgM (10).”
BackgroundResultSerology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
Lou, B., Li, T.-D., Zheng, S.-F., Su, Y.-Y., Li, Z.-Y., Liu, W., Yu, F., Ge, S.-X., Zou, Q.-D., Yuan, Q., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00763-2020 · Cited by 472 · cited 1×
“RDTs claiming to detect IgM were used to diagnose recent infections (11, 12).”
MethodAntibody response to SARS-CoV-2 infection in humans: A systematic review
Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C. I., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244126 · Cited by 374 · cited 1×
“Early in the pandemic, the utility of SARSCoV-2 serology testing was unknown but was used due to the lack of inexpensive point-of-care testing options and the long turnaround times for molecular diagnostics (7, 9, 10).”
BackgroundAbani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00163-5 · Cited by 369
T cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245532 · Cited by 350
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.
Infantino, M. G., Damiani, A., Gobbi, F. L., Grossi, V., Lari, B., Macchia, D., Casprini, P., Veneziani, F., Villalta, D., Bizzaro, N., et al. (2020) · PubMed · Cited by 146
Elslande, J. V., Oyaert, M., Lorent, N., Weygaerde, Y. V., Pottelbergh, G. V., Godderis, L., Ranst, M. A. V., André, E., Padalko, E. Y., Lagrou, K., et al. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115659 · Cited by 103 · cited 1×
“Furthermore, RDTs targeting anti-N antibodies alone were excluded because the literature indicated that anti-N antibody titers decay more quickly than anti-S antibodies and therefore may be less sensitive for the detection of past infection (20).”
BackgroundBlack, M. A., Shen, G., Feng, X., García-Beltrán, W. F., Feng, Y., Vasudevaraja, V., Allison, D., Lin, L. H., Gindin, T. S., Astudillo, M. G., et al. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112909 · Cited by 43 · cited 1×
“Some studies suggest a performance comparable to that with whole blood (18, 19).”
ResultRapid roll out of SARS-CoV-2 antibody testing—a concern
Andersson, M., Low, N., French, N., Greenhalgh, T., Jeffery, K., Brent, A., Ball, J., Pollock, A., McCoy, D., Iturriza-Gomara, M., et al. (2020) · BMJ · doi:10.1136/bmj.m2420 · Cited by 31 · cited 1×
“Few fi ndings were published in peer-reviewed journals (1 – 3).”
Backgroundvan den Beld, M. J. C., Murk, J., Kluytmans, J. A. J. W., Koopmans, M., Reimerink, J. H. J., van Loo, I. H. M., Wegdam-Blans, M. C. A., Zaaijer, H. L., SARS-CoV-2, S. W. F., GeurtsvanKessel, C. H., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00767-21 · Cited by 19
Dimech, W. J., Walker, S., Jardine, D. K., Read, S., Smeh, K., Karakaltsas, M., Dent, B., & Dax, E. M. (2004) · Accreditation and Quality Assurance · doi:10.1007/s00769-003-0734-5 · Cited by 17 · cited 1×
“The imprecision of quantitative tests should continually be monitored using a well-developed quality control (QC) program (16).”
MethodSelf-citationMacedo, A. C. L., Prestes, G. D. S., Colonetti, T., Cândido, A. C. R., Uggioni, M. L. R., Gomes, A. C., Silva, F. R., Ceretta, L. B., Grande, A. J., & da Rosa, M. I. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105121 · Cited by 16 · cited 1×
“The results of the seroconversion and late-seroconversion panels indicate that there was little evidence that the IgG response became undetectable within 7 weeks after infection, which is consistent with the results of other studies (10, 17).”
ResultFindeisen, P., Stiegler, H., Lopez‐Calle, E., Schneider, T., Urlaub, E., Hayer, J., & Zemmrich, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.164 · Cited by 12 · cited 1×
“Some studies suggest a performance comparable to that with whole blood (18, 19).”
ResultPeaper, D. R., Rhoads, D. D., Sullivan, K. V., Couturier, M. R., Humphries, R. M., Martin, I. W., Nolte, F. S., Rowlinson, M., She, R. C., Simner, P. J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01167-21 · Cited by 9 · cited 1×
“Numerous studies comparing the performances of test kits were published (2, 3, 6, 7), often as preprints (8), which were not subject to rigorous peer review (2, 7).”
Background
Research works printed but not linked: 4
- World Health Organization. 2020. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. World Health Organization, Geneva, Switzerland.
- Foundation for New and Innovative Diagnostics. 2020. FIND evaluation of SARS-COV-2 antibody (AB) detection tests. Foundation for New and Innovative Diagnostics, Geneva, Switzerland. https://www.finddx.org/covid-19/find-evaluations-of-sars-cov-2-assays/find-evaluations-of-sars-cov-2-ab-tests/. Accessed 29 April 2023.
- World Health Organization. 2020. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. World Health Organization, Geneva, Switzerland.
- World Health Organization Emergencies Preparedness. 2020. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection (version 2). World Health Organization, Geneva, Switzerland.
Cited by
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 141
Point-of-care testing: state-of-the art and perspectives
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0675 · Cited by 119
Self-citationComprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays
Dimech, W., Curley, S., & Cai, J. J. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03228-23 · Cited by 4
Self-citationGasana, P., Farnir, F., Gahamanyi, N., Kabalisa, E., Rutayisire, R., Mutesa, L., & Desmecht, D. J.-M. (2026) · Research Square · doi:10.21203/rs.3.rs-11245012/v1
Metadata
- Authors
- Dimech, W., Curley, S., Subissi, L., Ströher, U., Perkins, M. D., & Cunningham, J.
- Affiliations
- National Serology Reference Laboratory, Fitzroy, Australia
- World Health Organization (CH)
- Corresponding author
- Dimech, Wayne
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2023-06-15
- Volume
- 11
- Issue
- 3
- Pages
- e0510122-e0510122
- ISSN
- 2165-0497 (ISSN-L)
- PMC
- PMC10269659
- OpenAlex
- W4375954725
- Cited by
- 4
- References
- 17
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Microbiology Spectrum (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- World Health Organization (2022/1041859-0)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, rapid diagnostic tests, enzyme immunoassay, serological surveillance, diagnostic accuracy, seasonal human coronaviruses, MERS-CoV, SARS-CoV-1
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Testing, Antibodies, Viral, Humans, Clinical Laboratory Techniques, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.